Arthritis Awareness Month, observed every May, is a public health moment dedicated to something that affects more than 58 million adults in the United States alone. That number is expected to climb to 78 million by 2040, according to the Centers for Disease Control and Prevention (CDC). Yet despite how common arthritis is, many people remain uncertain about what it actually involves — and fewer still understand that the inflammation driving it is something that can be observed, measured, and tracked over time.
This Arthritis Awareness Month is a good time to look beyond the joint pain and ask a more probing question: What is actually happening inside the body, and how can measurable biology help us understand it?
What Arthritis Actually Is
Arthritis is not a single disease. It is an umbrella term covering more than 100 conditions that affect the joints, surrounding tissues, and connective tissue throughout the body. Two of the most common forms — osteoarthritis and rheumatoid arthritis — are fundamentally different in how they develop and what drives them.
Osteoarthritis vs. Rheumatoid Arthritis
Osteoarthritis (OA) is the most prevalent form, often described as “wear-and-tear” arthritis. It develops when the cartilage that cushions the ends of bones gradually breaks down, causing bones to rub against one another. This leads to pain, stiffness, and reduced range of motion, most commonly in the knees, hips, hands, and spine. OA is closely associated with aging, prior joint injuries, and mechanical stress — though inflammation still plays a contributing role in its progression.
Rheumatoid arthritis (RA) is an autoimmune condition, which means the immune system mistakenly attacks the synovial tissue that lines the joints. This immune-driven inflammation causes the joint lining to thicken, eventually damaging the cartilage and bone beneath it. RA tends to affect joints symmetrically — for example, both wrists or both knees simultaneously — and is associated with systemic effects beyond the joints, including fatigue and cardiovascular changes.
How Inflammation Drives Joint Changes
Inflammation is the body’s natural response to perceived threats — injury, infection, or, in the case of autoimmune disease, the body’s own tissue. Normally, inflammation resolves once the threat is neutralised. In conditions like RA, this inflammatory response becomes chronic, maintaining a state of low-level or high-level immune activity that can cause cumulative joint damage over time.
Even in osteoarthritis, research increasingly suggests that low-grade inflammation may accelerate cartilage loss and pain signaling. Understanding inflammation — including how to measure it — is central to understanding arthritis.
Why Arthritis Awareness Month Matters
The Scale of Arthritis in the U.S.
Arthritis is the leading cause of work disability in the United States. The Arthritis Foundation estimates that the condition costs the U.S. economy more than $300 billion annually in medical expenses and lost productivity. One in four adults reports experiencing severe joint pain associated with arthritis, and the condition disproportionately affects people’s ability to perform daily tasks and maintain quality of life.
Despite this burden, awareness of arthritis as a preventable, manageable, and biologically measurable condition remains relatively low. Many people attribute joint discomfort to aging and do not seek guidance until symptoms significantly limit their activity.
Who Is Most at Risk?
Several factors are associated with a higher likelihood of developing arthritis. Age is one of the strongest — the prevalence of OA increases significantly after age 50. Women are disproportionately affected, accounting for approximately 60% of all arthritis cases and the majority of RA diagnoses. Family history plays a role, particularly in RA, where genetic factors can increase susceptibility. People with obesity carry additional mechanical stress on weight-bearing joints, while prior joint injuries — even those that healed without apparent consequence — are associated with elevated OA risk later in life.
Key Biomarkers Linked to Arthritis
When clinicians evaluate joint symptoms, they typically order a panel of blood tests to help characterise what may be happening beneath the surface. These biomarkers do not diagnose arthritis on their own, but they offer valuable insight into the presence and degree of inflammation, as well as immune system activity.
CRP — A Marker of Systemic Inflammation
C-reactive protein (CRP) is a protein produced by the liver in response to inflammation. When inflammation is present anywhere in the body, CRP levels in the blood tend to rise. A high-sensitivity version of the test (hs-CRP) can detect subtler elevations that may reflect chronic low-grade inflammation.
CRP is not specific to arthritis — it can be elevated for many reasons, including infection, injury, and other inflammatory conditions. However, elevated CRP is commonly seen in active RA and can reflect the degree of systemic inflammatory activity. Tracking CRP over time helps individuals and their healthcare providers observe whether inflammation appears to be stable, increasing, or responding to lifestyle or therapeutic changes.
Rheumatoid Factor (RF) and Anti-CCP
Two biomarkers are particularly associated with rheumatoid arthritis: rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP).
Rheumatoid factor is an antibody that, when detected in the blood, is considered a marker associated with RA. However, RF is not highly specific — it can be elevated in other autoimmune conditions and even in some healthy individuals, particularly older adults. Its presence supports clinical suspicion of RA but does not confirm it on its own.
Anti-CCP antibodies are more specific to rheumatoid arthritis than RF. These antibodies target proteins that have undergone a particular chemical modification linked to the inflammatory process in RA. Anti-CCP testing is often ordered alongside RF because together they provide a more complete picture. Importantly, anti-CCP antibodies may be detectable before clinical symptoms fully develop, which makes them a subject of ongoing research interest in early identification contexts.
Neither RF nor anti-CCP provides a diagnosis independently. Clinical findings, symptom history, imaging, and a full evaluation by a rheumatologist are necessary to reach a diagnosis.
ESR and Supporting Tests (CBC, ANA, Uric Acid)
Erythrocyte sedimentation rate (ESR) measures how quickly red blood cells settle to the bottom of a tube over one hour. When inflammation is present, proteins in the blood cause red blood cells to clump together and fall more quickly, resulting in a higher ESR. Like CRP, ESR is a nonspecific marker — it reflects the presence of inflammation without identifying its source. It is often used alongside CRP to observe trends in inflammatory activity over time.
Supporting laboratory tests frequently ordered in arthritis workups include:
- Complete blood count (CBC): Provides a broad view of immune cell populations and can reveal anemia, which is common in chronic inflammatory conditions.
- Antinuclear antibody (ANA): Screens for autoimmune activity more broadly, often ordered when systemic lupus erythematosus or other autoimmune conditions are being considered alongside RA.
- Uric acid: Elevated uric acid levels are associated with gout, a form of inflammatory arthritis caused by uric acid crystal deposits in the joints. Differentiating gout from other forms of arthritis is important because it is managed differently.
What Inflammation Markers Can (and Cannot) Tell You
Screening vs. Diagnosis
Understanding the limits of biomarker testing is just as important as understanding what biomarkers measure. A single elevated CRP reading, for example, does not mean a person has arthritis. Inflammation can arise from many sources — a recent infection, a stressful week, or dietary patterns can all influence CRP in the short term.
Similarly, a negative RF or anti-CCP result does not rule out rheumatoid arthritis. Approximately 20–30% of people with RA are considered “seronegative,” meaning they test negative for these markers even with active disease. Diagnosis of arthritis requires clinical examination, symptom history, and in many cases, imaging studies such as X-rays or MRI.
Biomarkers provide useful information within a broader diagnostic context. They are not standalone answers — they are one piece of a larger puzzle that healthcare providers are trained to interpret.
Monitoring Trends Over Time
One of the most valuable applications of biomarker awareness is longitudinal tracking — measuring the same markers at regular intervals and observing how they change. A single data point tells a limited story. A series of CRP measurements taken over months, for example, can reveal whether inflammation appears stable, trending upward, or improving in response to lifestyle changes such as dietary shifts, weight loss, or increased physical activity.
This concept of trend monitoring is increasingly recognised as more informative than single-point snapshots. For individuals who are curious about their inflammatory baseline — particularly those managing risk factors like obesity, family history, or prior joint injury — serial testing can support more meaningful, ongoing conversations with healthcare providers.
Who May Benefit From Monitoring Arthritis Biomarkers
Adults Over 50
The risk of both osteoarthritis and rheumatoid arthritis increases with age. Adults in their 50s and beyond who experience morning stiffness, joint discomfort, or changes in mobility may find value in understanding their inflammatory markers as a starting point for discussion with a clinician.
Individuals With Family History
If a parent or sibling has been diagnosed with rheumatoid arthritis or another autoimmune condition, there may be an elevated genetic predisposition. Monitoring inflammatory markers over time can help individuals with family history stay engaged with their health data and have informed conversations with their physicians about what to watch for.
Women at Higher Risk
Women account for the majority of arthritis diagnoses, and RA is two to three times more common in women than in men. Hormonal factors are thought to play a role in immune regulation and susceptibility to autoimmune conditions. Women — particularly those in their 40s and beyond — who are curious about their inflammatory health may find biomarker awareness particularly relevant.
People With Obesity or Joint Injuries
Obesity is associated with elevated systemic inflammation, partly because adipose (fat) tissue produces inflammatory cytokines. This creates a physiological environment that may contribute to both OA progression and increased RA disease activity. Similarly, prior joint injuries — even minor ones — are associated with altered joint mechanics and a higher long-term risk of osteoarthritis. For individuals in these groups, understanding their CRP baseline may provide useful context for health management conversations.
Taking Ownership of Your Inflammation Markers
How Direct-to-Consumer Testing Works
Direct-to-consumer (DTC) lab testing allows individuals to order certain blood tests without requiring a physician’s referral. After a test order is placed, the individual visits a local certified laboratory or collection site, provides a blood sample, and receives results — typically through a secure digital platform.
For arthritis-related biomarkers, DTC testing can provide access to markers such as CRP, ESR, RF, anti-CCP, ANA, and uric acid. This approach supports health literacy and proactive awareness, giving individuals data to bring to their next healthcare conversation rather than waiting until symptoms become severe enough to prompt a clinical visit.
It is important to understand that DTC testing is a personal awareness and tracking tool. It does not replace a physician’s evaluation and should not be used to self-diagnose or self-treat.
Tracking CRP and Other Markers Longitudinally
The value of biomarker awareness grows significantly when testing is approached as an ongoing practice rather than a one-time event. Establishing a personal baseline — understanding what your CRP or ESR looks like when you feel well — creates a reference point that makes future results more meaningful.
For example, if your CRP typically registers at a certain level and then rises over several months alongside increasing joint stiffness, this pattern may prompt a more productive conversation with your healthcare provider than a single unexplained reading would. Longitudinal tracking helps you become a more informed participant in your own health story.
The Role of Awareness Months in Proactive Health
Arthritis Awareness Month serves a purpose that extends beyond recognition. It is an annual prompt to consider how much we understand about our own bodies — and how accessible that understanding has become.
Inflammation is not invisible. It has measurable correlates in the blood that can be tracked, observed, and used to support informed conversations with the clinicians who help us navigate our health. Arthritis is common, but being uninformed about the biology behind it does not have to be.
This May, consider going beyond awareness of symptoms. Learn what your inflammation markers look like. Ask your healthcare provider what they mean in the context of your risk factors, your family history, and your overall health picture. The goal is not to find answers in a single lab result — it is to develop a clearer, ongoing understanding of the biological processes your body is managing every day.
Proactive health ownership starts with curiosity. Biomarker literacy is one powerful way to make that curiosity actionable.
This article is for educational purposes only and does not constitute medical advice. Biomarker results should be interpreted by a qualified healthcare professional in the context of a full clinical evaluation. Direct-to-consumer testing supports health awareness and informed conversations — it does not diagnose, treat, or prevent any medical condition.
